Some basic requirements for preparing an antisickling herbal medicine -NIPRISAN®

African Journal of Pharmacy and Pharmacology

Volumn 3, Issue 5, 2009, Pages 259-264

  Ameh, S J ^a   Obodozie, O O ^a   Afolabi, E K ^a   Oyedele, E O ^a   Ache, T A ^a   Onanuga, C E ^a   Ibe, M C ^a   Inyang, U S ^a  

^a NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Nigeria)

Author keywords

Antisickling; Characteristics; Chemical manufacturing control; Herbal medicine; NIPRISAN ; Starting materials

Indexed keywords

ANTISICKLING AGENT; NIPRISAN; UNCLASSIFIED DRUG;

ARTICLE; CLOVE; DRUG SYNTHESIS; HERBAL MEDICINE; PHYSICAL CHEMISTRY; PIPER GUINEENSE; PIPERACEAE; PTEROCARPUS; PTEROCARPUS OSUN; SORGHUM; SORGHUM BICOLOR; WORLD HEALTH ORGANIZATION;

EID: 77953415768     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Awodogan A, Wambebe C, Gamaniel K, Okogun J, Orisadipe A, Akah P (1996) Acute and Short-term Toxicity of NIPRISAN® in Rats I: Biochemical Study. J. Pharmaceut. Res. Dev. 2: 39-45.
2. Bandaranayake WM (2003). Bandaranayake, Quality Control, Screening, Toxicity, and Regulation of Herbal Drugs. In: Modern Phytomedicine - Turning Medicinal Plants into Drugs. Edited by Iqbal Ahmad, Farrukh Aqil, and Mohammad Owais 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. pp. 25-57.
3. British Pharmacopoeia (2004). British Pharmacopoeia, Volume IV. The Stationery Office Limited, London. Appendix II D, Atomic spectrophotometry: emission and absorption, pp. A143-145. Determination of pH, pp. A143-145; Appendix VL, Determination of pH Values pp. A199-A200.
4. Cordeiro NJV, Oniyangi O (2006). Phytomedicines [medicines derived from plants] for sickle cell disease. The Cochrane Database of Systematic Review 2006 Issue 3. The Cochrane Library (ISSN 1464-780X).
5. Gamaniel K, Amos S, Akah P, Samuel B, Olusola A, Abayomi O, Okogun J, Wambebe C (1998). Pharmacological Profile of NIPRD 94/002/1-0: A Novel Herbal Antisickling Agent. J. Pharm. Res. Dev. 3: (2) 89-94.
6. th Annual Meeting of the National Sickle Cell disease Program, April 18-21, 2004, Los Angeles, California. Business Wire April 27, 2004.
7. Iyamu EW, Turner EA, Asakawa T (2003). Niprisan [Nix-0699] improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Brit. J. Haemat. (2003); 122(6): 1001-1008 10.1046/j.1365-2141.2003. 04536.x About DOI
8. Obodozie (2000). Obodozie OO. Standardization of Herbal Medicines. Being a Paper delivered at: Strategies to Strengthen the Utilization of Medicinal and Aromatic Plants in the National Health Care System. 11-13 July 2000. National Institute for Pharmaceutical Research and Development [NIPRD], Idu, Abuja, Nigeria.
9. Okore VC, Obimah DU (1998). Mechanism of the Laxative Actions of a Mineral Salt, Trona. J. Pharm. Res. Dev. 3(2) 72-74.
10. Pandey RC (2003). Xechem's Sickle Cell Drug, NIPRISAN -HEMOXIN-Granted Orphan Drug Status by the FDA NEW BRUNSWICK, N.J. - (BUSINESS WIRE)--Sept. 2, 2003 - Xechem International, Inc. (OTC BB: XKEM). Xechem's Sickle Cell Drug, NIPRISAN -HEMOXIN-Granted Orphan Drug Status by...???
11. Steinberg MH (1999). Management of Sickle Cell Disease. New Eng. J. Med. 340 (13): 1021-1030. http://content.nejm.org/cgi/content/full/3401/1021
12. Waknine Y (2005). Orphan Drug Niprisan (Nicosan/ Hemoxin) for Sickle Cell Disease in EU: The European Medicine Evaluation Agency has approved orphan drug status for the phytomedicine niprisan in the treatment of sickle cell disease. International Approvals. Oct. 25, 2005. http://www.medscape.com/px/viewindex/ more?Bucket=columns§ionId=2557.
13. Wambebe, CO, Elijah AB, Badru BO, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku SO, Nasipuri NR, Kunle OO, Okogun JI, Enwerem NM, Gamaniel, SK, Obodozie OO, Samuel, B, Fojule G, Ogunyale PO (2001a). Efficacy of Niprisan in the prophylactic management of patients with sickle cell disease. Current therapeutic research. 2001; 62(1): 26-34. ISSN 0011-393X CODEN CTCEA9. Efficacy of niprisan in the prophylactic management of patients with sickle cell disease. (Pubitemid 32493028)
14. Wambebe C, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku SO, Nasipuri NR, Kunle OO, Okogun, JI, Enwerem, NM, Gamaniel, SK, Obodozie, OO, Samuel, B, Fojule, G, Ogunyale PO (2001b). Double-blind, placebo-controlled, randomized cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine. 2001 Jul; 8(4):252-61. doi:10.1078/0944-7113-100040
15. WHO (1978) Declaration of Alma-Ata International Conference on Primary Health Care ... 12k - Adobe PDF - View as html International Conference on Primary Health Care, Alma-Ata, USSR, 6-12 September. 1978 ... care in accordance with the spirit and content of this Declaration. www.who.int/hpr/NPH/docs/ declaration-almaata.pdf
16. WHO (1998). Quality control methods for medicinal plant materials. Geneva: pp. 1-115.
17. WHO (2005a) Chemistry-Manufacturing-Control (CMC) considerations for herbal products p. 4.
18. WHO (2005b) APPENDIX 2 Glossary of key terms, p. 15. In; Information needed to support Clinical Trials of herbal products. TDR/GEN/Guidance/05. 1Operational Guidance: Special Programme for Research and Training in Tropical Diseases, 2005. WHO, Geneva, pp. 1-16.
19. WHO (2006). Sickle-cell disease and other haemoglobin disorders. August 2006, WHO, Geneva, Fact sheet No308.